MALAT1 and hepatocellular carcinoma: A previous in vivo study has demonstrated that MALAT1-targeted lentiviral shRNA inhibited tumor ontogenesis in heterograft models of HCC cells transformed by arsenite, enhancing the effects of MALAT1 on carcinogen-induced oncogenesis [10].